{"disease":{"id":"ipss-risk-category-intermediate-1","name":"ipss risk category intermediate 1"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03094637","title":"Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}